EXPRESSION OF GENES INVOLVED IN P53 PATHWAY REGULATION IN NEUROBLASTOMA: A SHORT REVIEW.

Q3 Medicine

Experimental oncology Pub Date : 2022-12-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-4.18960

M Inomistova, H Klymniuk, N Khranovska, S Pavlyk, E Shaida, A Gorbach, O Skachkova, D Shymon

{"title":"EXPRESSION OF GENES INVOLVED IN P53 PATHWAY REGULATION IN NEUROBLASTOMA: A SHORT REVIEW.","authors":"M Inomistova, H Klymniuk, N Khranovska, S Pavlyk, E Shaida, A Gorbach, O Skachkova, D Shymon","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-4.18960","DOIUrl":null,"url":null,"abstract":"<p><p>The search for new prognostic and stratification genetic and epigenetic markers in neuroblastoma is an urgent problem in pediatric oncology. The review summarizes recent progress in studying the expression of genes involved in p53 pathway regulation in neuroblastoma. Several markers associated with recurrence risk and poor outcome are considered. Among them are MYCN amplification, high MDM2 and GSTP1 expression and homozygous mutant allele variant of GSTP1 gene A313G polymorphism. Prognostic criteria for neuroblastoma based on the analysis of miR-34a, miR-137, miR-380-5p, and miR-885-5p expression involved in regulating p53-mediated pathway are also considered. The authors' research data on the role of the above markers in regulation of this pathway in neuroblastoma are presented. The study of alterations in expression of microRNAs and genes involved in p53 pathway regulation will not only expand our understanding of the mechanisms of neuroblastoma pathogenesis but could substantiate new approaches for delineating risk groups and risk stratification of neuroblastoma patients as well as treatment optimization based on the genetic characteristics of the tumor.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 4","pages":"266-271"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-4.18960","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The search for new prognostic and stratification genetic and epigenetic markers in neuroblastoma is an urgent problem in pediatric oncology. The review summarizes recent progress in studying the expression of genes involved in p53 pathway regulation in neuroblastoma. Several markers associated with recurrence risk and poor outcome are considered. Among them are MYCN amplification, high MDM2 and GSTP1 expression and homozygous mutant allele variant of GSTP1 gene A313G polymorphism. Prognostic criteria for neuroblastoma based on the analysis of miR-34a, miR-137, miR-380-5p, and miR-885-5p expression involved in regulating p53-mediated pathway are also considered. The authors' research data on the role of the above markers in regulation of this pathway in neuroblastoma are presented. The study of alterations in expression of microRNAs and genes involved in p53 pathway regulation will not only expand our understanding of the mechanisms of neuroblastoma pathogenesis but could substantiate new approaches for delineating risk groups and risk stratification of neuroblastoma patients as well as treatment optimization based on the genetic characteristics of the tumor.

查看原文本刊更多论文

神经母细胞瘤中p53通路调控相关基因的表达:简要综述。

寻找新的神经母细胞瘤预后和分层遗传和表观遗传标记是儿科肿瘤学的一个紧迫问题。本文综述了近年来神经母细胞瘤中p53 通路调控相关基因表达的研究进展。考虑了与复发风险和不良预后相关的几个标志物。其中MYCN扩增，MDM2 和GSTP1 高表达，GSTP1 基因A313G多态性纯合突变等位基因变异。基于miR-34a、miR-137、miR-380-5p和miR-885-5p参与调节p53介导途径的表达分析神经母细胞瘤的预后标准也被考虑。本文介绍了上述标记物在神经母细胞瘤中调控这一通路中的作用。研究参与p53 通路调控的microrna和基因的表达变化，不仅可以扩大我们对神经母细胞瘤发病机制的认识，而且可以为神经母细胞瘤患者的风险人群划分和风险分层以及基于肿瘤遗传特征的治疗优化提供新的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.